ArticleInternational journal of cancer2026
Global patterns and trends in kidney cancer incidence and mortality.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neoadjuvant lenvatinib and pembrolizumab for metastatic clear cell renal cell carcinoma: A potential opportunity for complete pathologic and radiographic response.Urology case reports · 2026Article
- Global patterns and trends in kidney cancer incidence and mortality.International journal of cancer · 2026Article
- Beyond the Usual: Breast, Pituitary and Gastric Metastases from Clear Cell Renal Cell Carcinomas-A Case Series with Review of Literature.Diagnostics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study provides an update on global patterns and trends in kidney cancer incidence and mortality. We used the most recent GLOBOCAN estimates, based on the best available data sources, including population-based cancer registries (PBCRs), to compare incidence and mortality in 185 countries or territories in 2022 and to assess time trends based on recorded PBCR and vital statistics data in 71 countries. Incidence age-standardised rates (ASRs) varied 10-fold across UN regions and 20-fold at the country level in 2022. Kidney cancer ASRs were consistently higher in males than females and ranged from 1.6 per 100,000 in low Human Development Index (HDI) countries to 12.6 in very high HDI countries among men and from 1.1 to 5.9 among women. The highest ASRs in males were in Belarus (22.9), Uruguay (20.5), and Latvia (19.2), and in females in Latvia (9.5), Uruguay (8.7), USA (8.7). While the patterns were similar for mortality, variations were less pronounced. The mortality-to-incidence ratio was lowest in Oceania (0.2) and highest in Africa (0.7). Over the past 15 years, incidence ASRs have tended to increase or stabilise in most European countries, Northern America and Oceania, but increased in Asia and Latin America. Mortality ASRs decreased in most countries, but increased in Portugal, Romania, Moldova, the Philippines, Malaysia and in 9 of 14 countries in Latin America. Regional variations in incidence call for a greater focus on risk factors amenable to prevention, coupled with an assessment of the role of diagnostics. The varied mortality patterns indicate present treatment inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.